Corporate | 22 November 2005 08:57

STRATEC: Market launch of ADVIA Centaur CP by Bayer HealthCare

Corporate-news transmitted by DGAP. The issuer is solely responsible for the content of this announcement. —————————————————————————— Market launch of ADVIA Centaur CP by Bayer HealthCare Birkenfeld, November 22, 2005 STRATEC Biomedical Systems AG (ISIN: DE0007289001) hereby announces that Bayer HealthCare, Diagnostics Division, a member of the Bayer Group (NYSE:BAY), has approved for sale the new ADVIA Centaur CP Immunoassay System which was developed for Bayer by STRATEC. “This market launch is a historic event which we have been working towards over the last three years. We expect this to produce convincing results, both in terms of our key figures and of the impact of increased market awareness levels,” commented Hermann Leistner, Chairman of the Board of Management at STRATEC Biomedical Systems AG. “ADVIA Centaur CP has been developed by STRATEC in close cooperation with our diagnostics partner Bayer. The successful product development undertaken by dovetailing the development, quality management and production processes of Bayer and STRATEC provides proof of our effectiveness and customer orientation,” stressed Dr. Claus Vielsack, Director of Immunoassay Systems at STRATEC Biomedical Systems AG. The supply of serial systems will be undertaken on the basis of an agreement outlined in the company’s ad-hoc announcement dated April 18, 2002. This agreement stipulates the purchase by Bayer over several years of a minimum volume commitment of analyzer systems. About ADVIA Centaur CP The Bayer HealthCare Diagnostics Division’s ADVIA series of innovative, cost- effective diagnostics systems for hospital and private laboratories covers the fields of hematology, immunodiagnostics, clinical chemistry and laboratory automation. Diseases such as breast and prostate cancer and disorders of the cardiovascular system as well as allergies and infectious diseases can be monitored using the ADVIA Centaur Immunoassay System. ADVIA Centaur CP (CP = compact) has been specially designed for small to medium-sized immunoassay laboratories. This routine system works just as reliably as the proven ADVIA Centaur system and guarantees the same level of quality. About Bayer HealthCare, Diagnostics Division Bayer HealthCare, Diagnostics Division (www.bayerdiag.com), based in Tarrytown, New York, U.S.A., is one of the largest diagnostic businesses in the world. The organization supports customers in 100 countries through an extensive portfolio of laboratory testing, molecular testing and near patient care diagnostics systems and services for use in the assessment and management of health, including the areas of cardiovascular and kidney disease, oncology, virology and women’s health. Bayer HealthCare Diagnostics Division’s global headquarters in the United States operates as part of Bayer HealthCare LLC, a member of the worldwide Bayer HealthCare group. About STRATEC STRATEC (http://www.stratec-biomedical.de) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (WKN: 728900 / ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, in the trading segment Gate-M of the Stuttgart Stock Exchange and on other exchanges. The STRATEC group comprises the listed holding company “STRATEC Biomedical Systems AG” as well as the wholly-owned subsidiaries “STRATEC NewGen GmbH” and “Robion AG”. Further information can be obtained from: STRATEC Biomedical Systems AG André Loy, Investor Relations Gewerbestrasse 37 75217 Birkenfeld Germany Tel: +49 7082 7916-190 Fax: +49 7082 7916-999 E-Mail: ir@stratec-biomedical.de End of announcement (c)DGAP 22.11.2005 —————————————————————————— WKN: 728900; ISIN: DE0007289001; Index: Listed: Geregelter Markt in Frankfurt (Prime Standard) und Stuttgart (Gate-M); Freiverkehr in Berlin-Bremen, Düsseldorf und München